Brant Binder

Co-Founder, SAB Member

Brant is a Co-Founder and past President of Psy Therapeutics. He is actively engaged in Psy’s scientific collaborations and financing and business development activities.

Before joining Psy, Brant was Co-Founder, President and CEO of X-Body Biosciences, which was sold to JUNO Therapeutics in 2015. In addition, Brant is a Co-Founder and former Board member of X-Chem Pharmaceuticals.

Prior to his involvement in the commercialization of DNA-encoded library platform companies, Brant co-founded and served as CEO of optical instrument company, SRU Biosystems. Brant began his career in venture capital and private equity investments at Trust Company of the West.

Brant received his MBA from MIT’s Sloan School of Management (where he was a seed investor in and BA from Georgetown University’s School of Foreign Service.